

#2/A
BP
10/24/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: GOODWIN et al.

Docket No.: 2804-I

Serial No.: -- not yet assigned --

for prior application:

Filed: July 28, 2000

Examiner: L. Spector

Group Art Unit: 1646

For: CD30 LIGAND (as amended)

PRELIMINARY AMENDMENT

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the above-identified application as follows, prior to examination:

In the Specification:

Page 1, line 7, delete the current title and replace with -- CD30 LIGAND --.

Page 1, line 10, after "This application is" insert -- a divisional of U.S. application
Serial No. 09/079,785, filed May 15, 1998, currently allowed, which is a divisional of U.S.
application Serial No. 08/580,014, filed December 20, 1995, now U.S. Patent 5,753,203,
which is a divisional of U.S. application Serial No. 08/225,989, filed April 12, 1994, now
U.S. Patent 5,480,981, which is --.

Page 1, line 11, delete "currently pending" and replace with -- now abandoned --.

In the Claims:

Cancel claims 1-26. Amend claims 27, 28 and 31 as follows:

27. (amended) A method of delivering a diagnostic or therapeutic agent to CD30⁺
cells, comprising contacting said cells with a conjugate [according to claim 25] comprising a
diagnostic or therapeutic agent attached to a CD30 ligand (CD30-L) polypeptide.

28. (amended) A method of delivering a diagnostic or therapeutic agent to CD30⁺
cells, comprising contacting said cells with a conjugate [according to claim 26] comprising a
diagnostic or therapeutic agent attached to a CD30-L polypeptide, wherein said CD30-L
polypeptide is a soluble fragment of the human CD30-L of SEQ ID NO:8.

A2
Sub
B1

A